TESARO (NASDAQ:TSRO) had its price objective decreased by Morgan Stanley from $165.00 to $156.00 in a report issued on Tuesday, January 16th, MarketBeat.com reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on TSRO. Citigroup restated a buy rating and issued a $135.00 target price (down previously from $216.00) on shares of TESARO in a research note on Wednesday, December 20th. HC Wainwright reiterated a buy rating and set a $158.00 price target on shares of TESARO in a research report on Friday, January 12th. Cowen reduced their price target on shares of TESARO from $125.00 to $80.00 and set a market perform rating on the stock in a research report on Tuesday, January 2nd. Zacks Investment Research downgraded shares of TESARO from a hold rating to a sell rating in a research report on Tuesday, October 17th. Finally, Piper Jaffray Companies reiterated a hold rating and set a $80.00 price target on shares of TESARO in a research report on Tuesday, January 2nd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Hold and an average price target of $149.97.
Shares of TESARO (NASDAQ TSRO) traded up $2.88 during trading on Tuesday, hitting $58.89. 916,032 shares of the stock were exchanged, compared to its average volume of 1,365,744. TESARO has a twelve month low of $55.02 and a twelve month high of $192.94. The firm has a market capitalization of $3,202.56, a PE ratio of -6.98 and a beta of 1.25. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
In other news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 40.50% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of TESARO by 5.6% in the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock valued at $337,039,000 after buying an additional 213,920 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after buying an additional 62,104 shares during the last quarter. State Street Corp boosted its holdings in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after buying an additional 177,057 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in TESARO by 24.9% during the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after purchasing an additional 178,406 shares during the last quarter. Finally, BB Biotech AG lifted its holdings in TESARO by 6.5% during the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after purchasing an additional 53,408 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: “TESARO (NASDAQ:TSRO) Price Target Cut to $156.00 by Analysts at Morgan Stanley” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://ledgergazette.com/2018/02/12/tesaro-tsro-price-target-cut-to-156-00-by-analysts-at-morgan-stanley.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.